Fundraising FoxSURGE
2 known investors
Find your way into SURGE
Sign up to see every warm intro you have to SURGE
- Paths you didn't know you had: your email and LinkedIn already hold routes to the SURGE team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SURGE develops clinical approaches for cancer immunotherapy and post-surgical cancer recurrence prevention. The company applies bioengineering and drug delivery innovations to address unmet oncology needs.
Founders & leadership
MG
Michael GoldbergCEOMichael Goldberg previously conducted research in academic settings with publications in top-tier journals including Cell, Nature, and Science. He is now CEO of SURGE, which develops localized drug delivery approaches for cancer immunotherapy during surgical tumor resection.
Investors · 2
Alumni Ventureslisted by Alumni VenturesManchester · $100K – $10M
How we know: av.vc · Not right? Tell us
Intuitive Ventureslisted by Intuitive VenturesSunnyvale
How we know: the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does SURGE do?
- SURGE develops clinical approaches for cancer immunotherapy and post-surgical cancer recurrence prevention. The company applies bioengineering and drug delivery innovations to address unmet oncology needs.
- Who are SURGE's investors?
- SURGE's investors include Alumni Ventures, Intuitive Ventures.